Comparison of Innovator vs. Biosimilar Ranibizumab in Treating Diabetic Macular Edema: A Multicenter Retrospective Study.

INTRODUCTION: To compare the efficacy of innovator ranibizumab (iRBZ-Accentrix, Novartis, India) vs. biosimilar ranibizumab (bRBZ, Razumab-Intas, India) in eyes with diabetic macular edema (DME) in an Indian population.
METHODS: Data of patients with DME who underwent at least three injections of iRBZ or bRBZ and had a minimum of 6 months follow-up were obtained from an electronic database. Choice of injection depended upon the patient. Pro re nata (PRN) protocol from baseline was used with reinjections advised if the central macular thickness (CMT) was at least 300 μm and best corrected visual acuity (BCVA) was 20/40 or worse. Primary outcome measure was comparison of change in BCVA at 6 months between iRBZ and bRBZ.
RESULTS: We included 264 eyes in the iRBZ group and 69 eyes in bRBZ group, which were comparable for baseline characteristics. Mean BCVA improved from 0.64 ± 0.39 logMAR to 0.47 ± 0.31 logMAR (p < 0.001) in the iRBZ group and from 0.71 ± 0.42 logMAR to 0.50 ± 0.29 logMAR in the bRBZ group (p < 0.001) at 6 months. There were no differences in BCVA between the two groups (p > 0.05 for all time points). The CMT reduction in the iRBZ group (120 ± 196 µm) was comparable to that in the bRBZ group at 6 months (105 ± 187 µm) (p = 0.69). There was no difference in the mean number of injections taken (3.81 ± 1.2 in iRBZ vs. 3.55 ± 1.2 in bRBZ) (p > 0.05) between groups. Vision at baseline was the only factor associated with vision at last follow-up after adjusting for CMT at baseline, type of injection, and number of injections.
CONCLUSIONS: Biosimilar RBZ is similar to innovator RBZ in improving vision and reducing CMT in eyes with DME in the short term.

Key Summary Points

Introduction

Diabetic macular edema (DME) is one of the leading causes of visual impairment globally and the increasing prevalence of diabetes means that there will be an exponential rise in the number of patients with DME [1, 2]. The treatment of DME has seen paradigm shifts in the last decade due to the use of intravitreal anti-vascular endothelial growth factor (anti-VEGF) agents [3]. Various trials under the Diabetic Retinopathy Clinical Research Network have clearly shown the efficacy of ranibizumab (Lucentis, Genentech, South San Francisco, CA, USA) and aflibercept (Eylea, Regeneron Pharmaceuticals, Inc, Tarrytown, New York, and Bayer HealthCare, Berlin Germany) in improving outcomes in eyes with DME [4]. However, the need for repeated treatments on a monthly basis leads to an increasing burden of treatment and affordability becomes an issue when patients are paying out of pocket, as happens in most of the developing world. Even though ranibizumab is available at a substantially reduced cost in India (Accentrix, Novartis India Ltd, Mumbai, India), patients still find it difficult to take repeated injections [5, 6].

In view of the increasing demand for anti-VEGF injections and the cost-prohibitive nature of treatment, retina physicians resort to the use of cheaper treatment options. Bevacizumab (Avastin, Genentech, South San Francisco, CA and Roche, Basel, Switzerland) is the commonest agent used in an off-label form globally and in a recent survey by the American Society of Retina Specialists, it was the commonest drug used in practice in the majority of the western world [7]. However, its use can be associated with cluster endophthalmitis as seen in India recently [8]. Biosimilars are very similar agents to approved reference biological products, with no clinically meaningful differences in terms of efficacy, safety, and immunogenicity [9]. These are generally available at lower costs compared to the innovator molecules and are another way to reduce cost of treatment. In India, a ranibizumab biosimilar (Razumab, Intas pharmaceuticals, Ahmedabad, India) was approved for intravitreal use in 2015 and has been increasingly adopted by retina physicians [10]. It has shown good efficacy for most retinal disorders in limited studies and more than 100,000 injections have already been used in India alone [11]. However, to the best of our knowledge, there are no comparative studies showing the efficacy of this biosimilar (bRBZ) with the innovator ranibizumab (iRBZ) molecule with up to 1-year follow-up.

Ours is a network of tertiary eye care centers and teaching hospitals in eastern India and we cater to more than a million patients annually. We have been increasingly adopting the bRBZ in our institution over the past 4 years as confidence in this molecule grows; currently, more than half of all our patients receive bRBZ. As an institutional protocol and in view of financial constraints faced by our patients, we use a pro re nata (PRN) regimen right from baseline in eyes with DME. In this study, we present a retrospective analysis of outcomes of bRBZ compared to iRBZ in eyes with DME in an Indian population.

Methods

This was a multicentric retrospective comparative study performed at a group of eye hospitals in eastern India. The study was conducted in accordance with the Declaration of Helsinki and was approved by the Master Ethical Committee of Disha Eye Hospitals in Kolkata and by the institutional review board at each center (Regn Number ECR/846/Inst/WB/2016/RR-19: EC-CT-2020-138). All patients gave informed consent before undergoing intravitreal injections. Data were collected from four centers within our hospital network and patients were treated by 10 fellowship trained retina specialists.

All patients over 18 years of age with a diagnosis of diabetic macular edema (ICD-9 coding) having a baseline visual acuity of 20/40 Snellen’s equivalent (0.3 logarithm of minimum angle of resolution, logMAR) or worse, who underwent intravitreal iRBZ or bRBZ for the first time across our hospital network between January 2015 and March 2020 were identified from a centralized electronic medical records system. All relevant data from those with a monthly follow-up of 6 months minimum and taken at least three injections during the first 6 months were entered into a datasheet. Only patients with a baseline HbA1c of 8.0 or less were included. Lastly, we included eyes matched for similar follow-up durations between the two injection groups for comparative analysis using statistical methods. A flowchart of the selection process is shown in Fig. 1. All patients with any diagnosis other than DME, significant pathology interfering with vision such as visually significant cataract, glaucoma, or any other pathologies causing macular edema and vitreoretinal interface disorders were excluded. Similarly, all eyes with any missing data such as best corrected visual acuity (BCVA) or macular thickness at any time point were also excluded. We also excluded eyes with DME and coexistent proliferative diabetic retinopathy, macular ischemia, previous intravitreal injections or retinal photocoagulation, or any previous vitreous surgery.

Fig. 1

Flowchart showing methods of inclusion of patients for the comparative study

All patient data including demographics, BCVA, intraocular pressure, slit lamp examination to assess the lens status, and fundus evaluation was recorded. This was followed by optical coherence tomography (OCT)-based assessment of the central macular thickness (CMT). Measurements were obtained using two different spectral domain OCT machines, namely Optovue OCT (Freemont, CA, USA) and at two centers and Spectralis OCT (Heidelberg, Germany) at two other centers. Automated CMT display was recorded at each visit from scans with a minimum image quality of 50%. The same machine was used for measurements at all time points for each patient; also the patients were examined at the same center on each visit. Fundus fluorescein angiography findings were recorded from case files when available.

Patients with DME were offered all information about the two injections, i.e., iRBZ (Accentrix, Novartis, India) and bRBZ (Razumab, Intas Pharmaceuticals, India), and informed about the potential need for repeated injections. The injection was based on the patient’s choice and drug affordability. As per our institutional protocol, we adopted a PRN retreatment regimen from baseline with monthly re-evaluation for the first 6 months. Reinjections were advised if the CMT was at least 300 μm and BCVA was 20/40 or worse at any time point during the first 6 months. The number of reinjections taken at each monthly time point was noted. Follow-up times were prolonged after 6 months, with increments of 2 weeks at a time, if reinjection was not required at the 6th month time point.

Comparison of change in visual acuity at 6 months time point (Δ BCVA = baseline BCVA − 6th month BCVA) between iRBZ and bRBZ was the primary outcome measure. Change in CMT, number of reinjections, and three-line gainers and losers were the secondary outcome measures.

All continuous variables were expressed as means with standard deviation or median with interquartile range (IQR) and group differences between continuous variables were analyzed using Student’s t test or Wilcoxon’s ranksum test for non-parametric distributions. Categorical variables were expressed as proportions (n, %) and group differences were analyzed using the chi-square or the Fischer’s exact test. Comparisons between parameters at baseline and at various time points during the study were done using the analysis of variance with Bonferroni adjustments.

Selection of matched eyes with respect to follow-up duration between innovator and biosimilar ranibizumab was done using the rangejoin command in STATA with a follow-up range for the innovator set within 1 month of the biosimilar. In view of repeated measures, a random effects linear regression model was used to determine factors influencing change in BCVA defined as BCVA at baseline minus BCVA at last follow-up.

All data was maintained in Microsoft Excel and analyzed using STATA 12.1 I/c (Stata Corp, Fort Worth, Texas, USA) and all p values less than 0.05 were considered statistically significant.

Results

Out of a possible 1902 eyes of 1677 unique patients that received either the iRBZ or bRBZ during the study period, inclusion criteria were satisfied by 403 eyes (21%) (Fig. 1). Following the matching process done for similar follow-up periods, we included 333 eyes of 303 patients in this analysis. Of eyes included, 264 received the iRBZ while the remaining 69 received the bRBZ. There were no differences in baseline characteristics, follow-up duration, and mean number of injections (Table 1) in iRBZ and bRBZ groups.

Table 1

Comparison between demographics, baseline vision, CMT, follow-up duration, and mean number of injections between innovator and biosimilar ranibizumab

Variable	Innovator RBZ (n = 264)	Biosimilar RBZ (n = 69)	p value
Age (years)	57.5 ± 3.8	58.6 ± 4.2	0.67
Gender (% men)	165 (62%)	42 (61%)	0.77
Eye (% right eye)	128 (48%)	34 (49%)	0.91
BCVA at baseline (logMAR)	0.64 ± 0.39	0.71 ± 0.42	0.18
CMT at baseline (μm)	457 ± 172	434 ± 153	0.40
Follow-up duration (months)	10.6 ± 5.5	10.7 ± 7.5	0.31
Mean number of injections	3.81 ± 1.2	3.55 ± 1.2	0.33

RBZ ranibizumab, BCVA best corrected visual acuity, CMT central macular thickness

The overall mean baseline BCVA improved from 0.66 ± 0.39 logMAR to 0.49 ± 0.32 at 3 months (p < 0.001) and then stabilized at 6 months (0.41 ± 0.31 logMAR, p = 0.18 compared to 3 months) and 1 year (0.39 ± 0.31 logMAR, p = 0.65 compared to 6 months) follow-up. Comparison of BCVA between the two groups (Fig. 2a) showed no differences at all time points (Table 2). There was a mean visual improvement of 0.24 ± 0.39 logMAR units overall at the last follow-up. A three-line gain in BCVA was seen in 146 eyes (44%) while a three-line loss was seen in 19 eyes (6%).

Fig. 2

Comparison of the a median best corrected visual acuity (with the 95% confidence intervals) and b median central macular thickness (with the 95% confidence intervals) between innovator and biosimilar ranibizumab groups

Table 2

Comparison of vision and macular thickness at different time points between the innovator and biosimilar ranibizumab

Variable	Innovator RBZ (n = 264)	Biosimilar RBZ (n = 69)	p value
BCVA comparisons (logMAR)
Baseline	0.64 ± 0.39	0.71 ± 0.42	0.18
1 month	0.48 ± 0.29**	0.55 ± 0.30**	0.32
3 months	0.49 ± 0.39	0.49 ± 0.25	0.72
6 months	0.47 ± 0.31	0.50 ± 0.29	0.61
9 months	0.37 ± 0.32 (n = 134)	0.47 ± 0.27 (n = 41)	0.17
12 months	0.38 ± 0.32 (n = 123)	0.44 ± 0.26 (n = 35)	0.25
Final visual acuity*	0.40 ± 0.36	0.44 ± 0.26	0.39
BCVA	0.24 ± 0.40	0.26 ± 0.34	0.71
% 3 line loss	18 (7%)	1 (1.5%)	0.14
% 3 line gain	114 (43%)	32 (46%)	0.63
CMT comparisons (μm)
Baseline	457 ± 172	434 ± 153	0.40
1 month	364 ± 152**	343 ± 126**	0.88
3 months	334 ± 147**	306 ± 97**	0.51
6 months	346 ± 162	326 ± 159	0.62
9 months	342 ± 161 (n = 134)	316 ± 150 (n = 41)	0.45
12 months	341 ± 161 (n = 134)	318 ± 150 (n = 41)	0.58
CMT final*	337 ± 160	328 ± 137	0.83
CMT	120 ± 196	105 ± 187	0.69

* Any time period

** p < 0.05 compared to previous time point

RBZ ranibizumab, CMT central macular thickness

Similarly, the overall mean CMT reduced from 452 ± 169 µm at baseline to 360 ± 145 µm at 1 month (p = 0.03), 325 ± 137 µm at 3 months (p = 0.03 compared to 1 month), and then remained stable at 342 ± 161 µm at 6 months (p = 0.31 compared to 3 months) and 336 ± 155 µm (p = 0.73 compared to 6 months) at 1-year follow-up. Comparison of CMT between the two groups (Fig. 2b) showed no differences at all time points (Table 2). Overall, the CMT reduced by 117 ± 196 µm at the last follow-up, with no statistically significant differences between groups (Table 2). There was no difference in the mean number of injections taken (3.81 ± 1.2 in iRBZ vs. 3.55 ± 1.2 in bRBZ) (p > 0.05) between groups. A total of 299 (90%) eyes required a loading dose [n = 240 in iRBZ (91%) and n = 59 (86%) in bRBZ group] but this was taken by only 139 (42%). None of the eyes included in this study experienced any adverse reactions such as intraocular inflammation or endophthalmitis, and none of the patients suffered any drug-related systemic adverse events such as thromboembolism, myocardial infarction, or stroke during the follow-up period.

Discussion

We found no differences in the visual and anatomical outcomes between treatment-naïve eyes with DME that received the innovator vs. the biosimilar ranibizumab. Overall, visual improvement or stabilization was seen in the majority of patients with very few experiencing three or more lines of visual loss in the short term. Visual recovery was seen from 1 month onwards in both groups and was sustained over time despite less than 50% adhering to the advised treatment regimens. The vision was consistently better by half a line in the iRBZ group right from baseline but differences were not significant at any of the time points. Macular edema also decreased over time and equally well in both groups.

The eyes in the iRBZ group received slightly more injections during the follow-ups (Table 3), but these differences were not statistically significant. However, a significantly greater proportion of eyes in the iRBZ group received a loading dose of three monthly injections in the first 3 months compared to bRBZ. On the basis of retreatment criteria, though 299 (90%) eyes required a loading dose only 139 (42%) actually went on to take the loading dose. In real-life scenarios, patients actually not being able to take loading dose of three injections is a reality and is depicted in our study also. A multivariable linear regression analysis using a random effects modeling showed that lower BCVA at baseline was the only factor associated with significantly more gain in vision at last follow-up (every one-line worsening in baseline BCVA was associated with 0.06 logMAR greater gain in vision, 95% CI = 0.053–0.071 logMAR, p < 0.001) after adjusting for CMT at baseline, type of injection, and number of injections. A correlation between BCVA at baseline and last follow-up is shown in Fig. 3.

Table 3

Comparison of number of injections in the innovator and biosimilar groups

Variable	Innovator RBZ (n = 264)	Biosimilar RBZ (n = 69)	p value
3 injections	141 (53%)	50 (72.5%)	0.13
4 injections	74 (28%)	11 (16%)
5 injections	23 (9%)	3 (4%)
6 injections	14 (5%)	2 (3%)
7 injections	7 (3%)	1 (1.5%)
8 injections	4 (1.5%)	1 (1.5%)
9 injections	1 (0.5%)	1 (1.5%)
% eyes receiving 3 loading doses	118 (45%)	21 (30%)	0.004

RBZ ranibizumab, CMT central macular thickness

Fig. 3

Scatter plot with a locally weighted smoothening curve showing the correlation between best corrected visual acuity at baseline and last follow-up

The availability of biosimilars has added to our armamentarium of anti-VEGF drugs and enabled us to offer retreatments at reduced costs [5, 9]. However, lack of comparative studies with a significant period of follow-up with the innovator molecule has led to skepticism amongst physicians and has prevented widespread adoption. Our results are encouraging and should alleviate concerns about efficacy of the biosimilar for management of DME. Previous non-comparative studies using the same biosimilar have also shown good results in eyes with DME. In the recently published CESAR study [12], Verma et al. report excellent visual outcomes from 57 treatment-naïve DME eyes (median of 0.5 logMAR to 0.2 logMAR at 3 months) that received bRBZ as a PRN protocol from baseline. They also report improvement in CMT from 436.70 ± 174.33 μm at baseline to 275.04 ± 120.09 μm at 3 months. In another retrospective study on 44 Indian eyes with DME, Sameera et al. showed a one-line visual improvement at 1 month using bRBZ for both treatment-naïve (n = 18) and pretreated eyes [13]. Similarly, the macular thickness also reduced from 366.8 ± 93.9 μm to 311.6 ± 83.2 μm (p < 0.001), similar to our results. Since Sameera et al.’s study was preliminary, they performed electroretinography for all patients, which did not show any appreciable changes at 1 month [13]. However, in their study, further follow-up was lacking, making it difficult to interpret the efficacy of the drug. In a more recent study, Gopal et al. retrospectively studied 120 eyes with DME and again showed similar visual improvement from 0.59 to 0.47 logMAR units and CMT reduction from 393 μm to 321 μm at 1 month using bRBZ, similar to our results [14]. However, follow-up data beyond 1 month was again lacking. In a large retrospective multicentric study (RE-ENACT study) pooling data from 17 centers across India, Sharma et al. reported treatment outcomes using bRBZ in 341 eyes with various retinal conditions of which 103 eyes had DME [15]. Though the authors do not provide outcomes for individual disease pathologies, they show significant cumulative visual improvement in the majority of eyes. Our study is the first with up to 12 months follow-up comparing iRBZ and bRBZ in eyes with DME and shows sustained visual gains maintained at final follow-up, despite PRN treatment protocols from baseline.

In resource-poor settings where payments are predominantly out of pocket, most patients find it hard to adopt monthly loading doses for the first 3 months. Additionally, patients’ lower educational status also means that they fail to perceive the benefits of treatment and are often unsatisfied with visual outcomes [6]. These factors mean that the majority of physicians in the developing world, including India, are forced to adopt a PRN treatment protocol from baseline, as evidenced by a lot of studies published from the region [10, 12, 16]. Previous studies from the west have also shown that about a third of the patients can do well even without the loading dose, provided a close follow-up can be maintained and reinjections given at the first instance of requirement based on established retreatment criteria [17]. Our results and others show that the majority of eyes maintain vision and almost half experience good visual gain adopting this strategy. Given the financial and other constraints, a PRN strategy from baseline with strict follow-up and timely reinjections can be adopted in resource-poor settings to minimize the number of injections without losing treatment benefit in eyes with DME. On the basis of our results, we also believe that patients with DME adopting the PRN from baseline should be counseled about the need for a minimum of four injections in the first year in addition to the burden of monthly follow-up visits and OCT scans for at least the first 6 months.

The merits of our study are the relatively large sample size and comparisons between iRBZ and bRBZ, with 12 months follow-up, that have not been reported in the past, to the best of our knowledge. However, strict inclusion criteria meant that many patients who did not take injections as advised and did not undergo follow-up were excluded. Additionally, having different OCT machines across centers may introduce an element of error in the overall CMT results, though using the same machine at all visits may minimize estimates.

Conclusion

The bRBZ performed as well as the iRBZ in terms of visual outcomes and reductions in macular thickness over 1-year follow-up. Adopting a PRN regimen from baseline to treat DME may be a viable strategy in resource-poor settings like ours but overall results may be still inferior to more frequent injections. On the basis of our results, bRBZ can be adopted by more vitreoretina specialists so that the cost of treatment can be brought down further without compromising on visual and anatomic results.

Why carry out this study?

Biosimilars of anti-vascular endothelial growth factor (anti-VEGF) drugs are an appealing therapeutic alternative to the parent biologic since they have the potential to reduce the cumulative cost of treatment in various chorioretinal disorders. Although the Indian drug regulator-approved ranibizumab biosimilar Razumab (Intas Pharmaceuticals, Ahmedabad, India) has demonstrated good efficacy and safety based on phase III studies, the limited number of patients treated in a controlled environment may not truly reflect the delivery settings and the population diversities in real-world scenarios.

What was learned from the study?

In a real-world setting, biosimilar ranibizumab is similar to innovator ranibizumab in improving vision and reducing central macular thickness (CMT) in eyes with diabetic macular edema (DME) in the short term. Intravitreal biosimilar ranibizumab has an acceptable ocular and systemic safety profile in patients with diabetic macular edema.